Can-Fite BioPharma (CANF) Profit After Tax Growth (3y) (2017 - 2023)
Can-Fite BioPharma (CANF) Profit After Tax Growth (3y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -29.12% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 59.34% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 23.10% |
| Sep 30, 2023 | 11.88% |
| Jun 30, 2023 | 10.86% |
| Mar 31, 2023 | 14.52% |
| Dec 31, 2022 | 53.53% |
| Sep 30, 2022 | 4.98% |
| Jun 30, 2022 | 31.19% |
| Mar 31, 2022 | -49.31% |
| Dec 31, 2021 | -83.28% |
| Sep 30, 2021 | 176.80% |
| Jun 30, 2021 | 51.66% |
| Mar 31, 2021 | -45.67% |
| Dec 31, 2020 | -108.96% |
| Sep 30, 2020 | -59.81% |
| Jun 30, 2020 | -41.04% |
| Mar 31, 2020 | -35.66% |
| Dec 31, 2019 | 29.40% |
| Sep 30, 2019 | -49.01% |
| Jun 30, 2019 | -89.04% |
| Mar 31, 2019 | 6.03% |